[go: up one dir, main page]

BRPI0519026A2 - arranjos de antÍgeno de il-15 e usos dos mesmos - Google Patents

arranjos de antÍgeno de il-15 e usos dos mesmos

Info

Publication number
BRPI0519026A2
BRPI0519026A2 BRPI0519026-6A BRPI0519026A BRPI0519026A2 BR PI0519026 A2 BRPI0519026 A2 BR PI0519026A2 BR PI0519026 A BRPI0519026 A BR PI0519026A BR PI0519026 A2 BRPI0519026 A2 BR PI0519026A2
Authority
BR
Brazil
Prior art keywords
composition
antigen
provides
arrangements
mutein
Prior art date
Application number
BRPI0519026-6A
Other languages
English (en)
Inventor
Patrik Maurer
Martin Bachmann
Yu Zou
Alain Tissot
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of BRPI0519026A2 publication Critical patent/BRPI0519026A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ARRANJOS DE ANTÍGENO DE IL-15 E USOS DOS MESMOS. A presente invenção refere-se aos campos da biologia molecular, virologia, imunologia e medicina. A invenção fornece uma composição compreendendo um arranjo de antígeno ordenado e repetitivo, em que o antígeno é uma proteína de IL-15, uma muteina de IL-15 ou um fragmento de IL-1 5. Mais especificamente, a invenção fornece uma composição compreendendo uma partícula semelhante a vírus, e pelo menos uma proteína de IL-15, muteina de IL-15 ou pelo menos um fragmento de IL-15 ligante à esta. A invenção também fornece um processo para produzir a composição. As composições da invenção são úteis na produção de vacinas para o tratamento de doenças inflamatórias e auto-imunes crônicas. A composição da invenção eficientemente induz respostas imunes, em particular respostas de anticorpo. Além disso, as composições da invenção são particularmente úteis para induzir eficientemente respostas imunes auto-específicas dentro do contexto indicado.
BRPI0519026-6A 2004-12-13 2005-12-12 arranjos de antÍgeno de il-15 e usos dos mesmos BRPI0519026A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63517904P 2004-12-13 2004-12-13
PCT/EP2005/056680 WO2006063974A2 (en) 2004-12-13 2005-12-12 Il-15 antigen arrays and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0519026A2 true BRPI0519026A2 (pt) 2008-12-23

Family

ID=36192618

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519026-6A BRPI0519026A2 (pt) 2004-12-13 2005-12-12 arranjos de antÍgeno de il-15 e usos dos mesmos

Country Status (14)

Country Link
US (1) US20090123414A1 (pt)
EP (1) EP1830875A2 (pt)
JP (1) JP2008523132A (pt)
KR (1) KR20070089186A (pt)
CN (1) CN101076352A (pt)
AU (1) AU2005315658A1 (pt)
BR (1) BRPI0519026A2 (pt)
CA (1) CA2590778A1 (pt)
IL (1) IL183457A0 (pt)
MX (1) MX2007006832A (pt)
NZ (1) NZ555590A (pt)
RU (1) RU2007126553A (pt)
WO (1) WO2006063974A2 (pt)
ZA (1) ZA200704908B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
EP2338510A1 (en) * 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP2619229B1 (en) 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
JP2014502258A (ja) 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
EP2794662A1 (en) 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US10548957B2 (en) 2012-09-28 2020-02-04 Dana-Farber Cancer Institute, Inc. Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
KR102503476B1 (ko) 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
EA035378B1 (ru) 2015-01-15 2020-06-04 Юниверсити Оф Копенгаген Вирусоподобная частица с эффективным экспонированием эпитопов
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
EP3368068B1 (en) 2015-10-30 2020-11-18 University of Copenhagen Virus like particle with efficient epitope display
JP7142630B2 (ja) 2016-10-14 2022-09-27 ゼンコア インコーポレイテッド ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質
SG11201903306SA (en) 2016-10-21 2019-05-30 Altor Bioscience Corp Multimeric il-15-based molecules
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
US11377477B2 (en) 2018-10-12 2022-07-05 Xencor, Inc. PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20230192797A1 (en) * 2020-05-18 2023-06-22 Jiangsu Simcere Pharmaceutical Co., Ltd. Human il-15 mutant and uses thereof
WO2024263698A1 (en) * 2023-06-22 2024-12-26 Memorial Sloan-Kettering Cancer Center Anti-pd-l1 immunoglobulin-related compositions comprising il-15-il-15ra fusion polypeptides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1359312A (fr) * 1963-03-14 1964-04-24 Siderurgie Fse Inst Rech Perfectionnements aux procédés de dégazage des métaux en fusion
US3700429A (en) * 1970-01-05 1972-10-24 Allegheny Ludlum Steel Method of controlling vacuum decarburization
JPS6173817A (ja) * 1984-09-18 1986-04-16 Sumitomo Electric Ind Ltd 溶鋼制御精錬法および精錬装置
US4918705A (en) * 1989-07-06 1990-04-17 General Electric Company Furnace enclosure having a clear viewpath
JP2002508748A (ja) * 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
NZ531211A (en) * 2001-08-23 2007-04-27 Genmad As Human antibodies specific for interleukin 15 (IL-15)
ES2335979T3 (es) * 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
BR0213950A (pt) * 2001-11-07 2004-08-24 Cytos Biotechnology Ag Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
EP1441764B1 (en) * 2001-11-07 2008-10-29 Cytos Biotechnology AG Antigen arrays comprising rankl for treatment of bone disease
EP2351770A1 (en) * 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
ATE441429T1 (de) * 2002-07-19 2009-09-15 Cytos Biotechnology Ag Ghrelin-träger-konjugate

Also Published As

Publication number Publication date
US20090123414A1 (en) 2009-05-14
IL183457A0 (en) 2007-09-20
WO2006063974A2 (en) 2006-06-22
AU2005315658A1 (en) 2006-06-22
ZA200704908B (en) 2008-10-29
CN101076352A (zh) 2007-11-21
MX2007006832A (es) 2007-08-07
RU2007126553A (ru) 2009-01-20
JP2008523132A (ja) 2008-07-03
KR20070089186A (ko) 2007-08-30
EP1830875A2 (en) 2007-09-12
WO2006063974A3 (en) 2006-08-17
CA2590778A1 (en) 2006-06-22
NZ555590A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
BRPI0519026A2 (pt) arranjos de antÍgeno de il-15 e usos dos mesmos
BR0213950A (pt) Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
BRPI0511751A (pt) usos médicos de conjugados veìculos de peptìdeos de tnf não-humano
BRPI0516775A (pt) ensaios de polipeptìdeo de antìgeno de inibidor gástrico (gip) e seus usos
DE60230963D1 (de) Molekulare anordnung von amyloid beta antigenen
BRPI0707779B8 (pt) antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
ECSP055551A (es) Composiciones de vacunas que contienen arreglos de antígeno amiloide beta 1-6
DE60329106D1 (de) Ghrelin-träger-konjugate
BR0213941A (pt) Arranjos de antìgeno para o tratamento de doença óssea
ES2154738T3 (es) Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
HRP20140419T1 (hr) Molekule za vezanje koje mogu neutralizirati virus bjesnoä†e i njihova uporaba
BRPI0620946A8 (pt) anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
ATE494910T1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
BRPI0516953A (pt) partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico
CY1112895T1 (el) Μεταβολη της ισορροπιας τη1/τη2 στα διαχωρισμενα αντιγριπικα εμβολια με ανοσοενισχυτικα
NO20012135D0 (no) Forsterkede vaksiner
BRPI0507002A (pt) conjugados veìculos de grelina
WO2023196658A3 (en) Antibody compositions and optimization methods
MXPA04003901A (es) Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.
WO2003059386A3 (en) Prion protein carrier-conjugates
MXPA04003900A (es) Disposiciones de antigenos para el tratamiento de enfermedades oseas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.